Associate Director, IT GxP & Quality Systems
ProKidney
Associate Director, IT GxP & Quality Systems
ProKidney
Develops cell therapy to treat CKD
The Associate Director, IT GxP & Quality Systems, leads strategic programs within the Company's regulated technology landscape and serves as the primary technology partner for Quality Systems. This role is accountable for the delivery, governance, optimization, compliance, and lifecycle management of GxP technology platforms, with primary ownership of the Quality Management Systems (QMS) environment.
The role drives technology solutions that enable compliant business processes across Quality, Clinical, Regulatory, Manufacturing, Technical Operations, and other GxP-regulated functions. The Associate Director connects technology execution with departmental strategy, ensuring systems scale effectively to support the organization's evolving clinical, manufacturing, and commercialization needs. The role leads cross-functional initiatives, manages external partners, and continuously improves Quality Systems capabilities while maintaining regulatory compliance and inspection readiness. The Associate Director level is characterized by leading programs with strategic impact, driving outcomes at scale, and connecting execution to departmental strategy with emphasis to transform processes to support commercialization.
Key Responsibilities:
GxP & Quality Systems Leadership
Technology Delivery & Portfolio Management
Compliance & Validation
Cross-Functional Leadership
Vendor & Partner Management
Qualifications:
ProKidney is an equal employment opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law.
Applicants must be eligible to work in the United States without the need for work visa or residency sponsorship.
ProKidney develops rilparencel, a cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD). The product is in late-stage clinical trials, and the goal is to delay or potentially avoid the need for dialysis by slowing the loss of kidney function. The treatment works by using transplanted or administered cells to support kidney tissue and function, offering a therapeutic option beyond standard care. ProKidney plans to commercialize rilparencel through sales to healthcare providers and direct-to-patient access, with potential partnerships with providers and insurers to expand access. The company differentiates itself by pursuing a first-in-class cell therapy specifically for CKD and focusing on a large, underserved patient population in the United States. Its mission is to transform CKD care by providing a treatment that preserves kidney function and reduces the burden of dialysis for millions of patients.
Explore more opportunities at ProKidney